RxDoctor Payments Data

Michael Fomby, DO

Internal Medicine · Kansas City, MONPI 1497031967

Payments from drug & device makers

$11,270in general payments, 2019–2025

Across 664 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • AstraZeneca$1K
  • Amgen$658
  • Abbott$588
  • plus $5K from 50 others

What the payments were for

  • Food & beverage$11,270100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,270 in reported general payments places this provider in the 95th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$133,678
Medicare patients
269
Services billed
4,652

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide110$140,625
EliquisApixaban71$84,338
MounjaroTirzepatide57$62,640
JardianceEmpagliflozin46$52,767
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$52,471
XareltoRivaroxaban21$33,480
XifaxanRifaximin11$33,351
RybelsusSemaglutide15$30,494
JanuviaSitagliptin Phosphate16$24,231
ProliaDenosumab11$18,954
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$13,241
SymbicortBudesonide/Formoterol Fumarate23$10,468
VascepaIcosapent Ethyl18$10,172
MyrbetriqMirabegron16$9,969
FarxigaDapagliflozin Propanediol19$9,396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,099$171,119125 claims
PfizerEliquis, Paxlovid$415$87,11684 claims
Lilly USA, LLCMounjaro$1,065$62,64057 claims
GSKTrelegy Ellipta, Arexvy$176$59,46388 claims
Boehringer IngelheimJardiance$279$52,76746 claims
Johnson & JohnsonXarelto$105$33,48021 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$244$33,35111 claims
AstraZenecaBreztri Aerosphere, Symbicort, Farxiga$1,016$33,10562 claims
MerckJanuvia$272$24,23116 claims
AmgenProlia$658$18,95411 claims
Astellas Pharma US IncMyrbetriq$178$9,96916 claims
AbbVieSynthroid$1,620$3,16740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →